Stemline Therapeutics Announces Oral Presentation of Positive Phase I/II Trial Results with Novel Brain Cancer Vaccine at ASCO

Stemline Therapeutics, Inc. Announces Oral Presentation of Positive Phase I/II Trial Results with Novel Brain Cancer Vaccine at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting

Stemline Therapeutics, announced that clinical results from a multi-epitope brain cancer vaccine, that Stemline has licensed from the University of Pittsburgh (Pitt) and is further developing as SL-701, will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago

NEW YORK, NY, USA | June 2, 2011 | Stemline Therapeutics, Inc. today announced that clinical results from a multi-epitope brain cancer vaccine, that Stemline has licensed from the University of Pittsburgh (Pitt) and is further developing as SL-701, will be presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago, IL, on Monday, June 6, 2011 at 1 PM CT. Dr. Hideho Okada, Associate Professor of Neurological Surgery at Pitt, will deliver the presentation.

Dr. Okada and his colleagues conducted a Phase I/II trial of a single agent vaccine in patients with advanced malignant gliomas. Their most recent findings include two durable complete responses (CRs) as measured by MRI, one of which is ongoing at 18 months in a patient with recurrent glioblastoma, and partial responses (PRs) in two other patients. A survival benefit was also observed in these recurrent/refractory patients. A second Phase I/II trial in malignant glioma, which utilizes a subcutaneously delivered peptide cocktail, has demonstrated efficacy including one patient who sustained a greater than 50% tumor shrinkage. This trial is currently ongoing. To date, the vaccine has been well-tolerated. Positive immunological responses were also observed in a majority of treated patients. Details on the presentation are as follows:

Phase I/II vaccine study targeting novel HLA-A2-restricted CTL epitopes in combination with poly-ICLC in patients with recurrent malignant glioma
 Abstract #: 2506
 Lead Author: Hideho Okada, MD, PhD, University of Pittsburgh
 Session: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy
 Date/Time: Monday, June 6, 1:00 PM to 4:00 PM CT
 Location: McCormick Place Arie Crown Theater

A copy of the above referenced abstract can be viewed online through the ASCO website at www.asco.org.

About Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells (CSCs) and tumor bulk. SL-401, the Company's lead program, has completed a multicenter Phase I/II trial in advanced stage acute myeloid leukemia (AML) where it has demonstrated single agent activity including two durable complete responses (CRs) and an overall survival (OS) benefit, and is now poised for later stage studies. SL-401 is also currently being tested in additional indications, including chronic myeloid leukemia (CML) and myelodysplastic syndrome (MDS) at the MD Anderson Cancer Center. The Company's second clinical program, now being developed as SL-701, has completed a Phase I/II trial at the University of Pittsburgh in patients with recurrent malignant glioma (brain cancer) where it has demonstrated single agent activity including two durable CRs and an OS benefit. SL-701 is now poised for later stage trials in adult and pediatric patients with advanced brain cancer. Stemline is also developing a broad portfolio of pre-clinical small molecules and antibodies for a variety of solid and hematological cancer types. Many of these compounds have derived from StemScreen®, the Company's proprietary discovery platform. For more information, please visit the Company's website at www.stemline.com.

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.